Donato DiMonte

Prof. Donato DiMonte


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Neurobiology of Disease
Verified
Journal Article
Closed access
AMAlison L. McCormack
Alison L. McCormack
MTMona Thiruchelvamb
Mona Thiruchelvamb
AMAmy B. Manning-Bog
Amy B. Manning-Bog
CTChristine Thiffaulta
Christine Thiffaulta
JLJ. William Langstona
J. William Langstona
DDDonato DiMonte
Donato DiMonte

1 January 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AMAmy B. Manning-Bog
Amy B. Manning-Bog
AMAlison L. McCormack
Alison L. McCormack
JLJie Li
Jie Li
VUVladimir N. Uversky
Vladimir N. Uversky
AFAnthony L. Fink
Anthony L. Fink
DDDonato DiMonte
Donato DiMonte
α-Synuclein-containing aggregates represent a feature of a variety of neurodegenerative disorders, including Parkinson's disease (PD). However, mechanisms that promote intraneuronal α-synuclein assembly remain poorly understood. Because pesticides, particularly the herbicide paraquat, have been suggested to play a role as PD risk factors, the hypothesis that interactions between α-synuclein and these environmental agents may contribute to aggregate formation was tested in this study. Paraquat markedly accelerated the in vitro rate of α-synuclein fibril formation in a dose-dependent fashion. When mice were exposed to the herbicide, brain levels of α-synuclein were significantly increased. This up-regulation followed a consistent pattern, with higher α-synuclein at 2 days after each of three weekly paraquat injections and with protein levels returning to control values by day 7 post-treatment. Paraquat exposure was also accompanied by aggregate formation. Thioflavine S-positive structures accumulated within neurons of the substantia nigra pars compacta, and dual labeling and confocal imaging confirmed that these aggregates contained α-synuclein. The results suggest that up-regulation of α-synuclein as a consequence of toxicant insult and direct interactions between the protein and environmental agents are potential mechanisms leading to α-synuclein pathology in neurodegenerative disorders.

1 March 2003 in Neuron
Verified
Journal Article
Closed access
DKDeepinder Kaur
Deepinder Kaur
FYFerda Yantiri
Ferda Yantiri
SRSubramanian Rajagopalan
Subramanian Rajagopalan
JKJyothi Kumar
Jyothi Kumar
JMJun Qin Mo
Jun Qin Mo
JAJulie K Andersen
Julie K Andersen

25 July 2007 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
WCW. Michael Caudle
W. Michael Caudle
Jason RichardsonJason Richardson
Jason Richardson
MWMin Z. Wang
Min Z. Wang
TTTonya N. Taylor
Tonya N. Taylor
TGThomas S. Guillot
Thomas S. Guillot
GMGary W. Miller
Gary W. Miller
The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the dopamine system. Here, we show that mice that express ∼5% of normal VMAT2 (VMAT2 LO) display age-associated nigrostriatal dopamine dysfunction that ultimately results in neurodegeneration. Elevated cysteinyl adducts tol-DOPA and DOPAC are seen early and are followed by increased striatal protein carbonyl and 3-nitrotyrosine formation. These changes were associated with decreased striatal dopamine and decreased expression of the dopamine transporter and tyrosine hydroxylase. Furthermore, we observed an increase in α-synuclein immunoreactivity and accumulation and neurodegeneration in the substantia nigra pars compacta in aged VMAT2 LO mice. Thus, VMAT2 LO animals display nigrostriatal degeneration that begins in the terminal fields and progresses to eventual loss of the cell bodies, α-synuclein accumulation, and anl-DOPA responsive behavioral deficit, replicating many of the key aspects of Parkinson's disease. These data suggest that mishandling of dopamine via reduced VMAT2 expression is, in and of itself, sufficient to cause dopamine-mediated toxicity and neurodegeneration in the nigrostriatal dopamine system. In addition, the altered dopamine homeostasis resulting from reduced VMAT2 function may be conducive to pathogenic mechanisms induced by genetic or environmental factors thought to be involved in Parkinson's disease.

26 December 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
BRB. Ripley
B. Ripley
SOSebastiaan Overeem
Sebastiaan Overeem
NFN. Fujiki
N. Fujiki
Soňa NevšímalováSoňa Nevšímalová
Soňa Nevšímalová
MUM. Uchino
M. Uchino
SNS. Nishino
S. Nishino
Objective: To examine the specificity of low CSF hypocretin-1 levels in narcolepsy and explore the potential role of hypocretins in other neurologic disorders. Methods: A method to measure hypocretin-1 in 100 μL of crude CSF sample was established and validated. CSF hypocretin-1 was measured in 42 narcolepsy patients (ages 16–70 years), 48 healthy controls (ages 22–77 years,) and 235 patients with various other neurologic conditions (ages 0–85 years). Results: As previously reported, CSF hypocretin-1 levels were undetectably low (<100 pg/mL) in 37 of 42 narcolepsy subjects. Hypocretin-1 levels were detectable in all controls (224–653 pg/mL) and all neurologic patients (117–720 pg/mL), with the exception of three patients with Guillain–Barré syndrome (GBS). Hypocretin-1 was within the control range in most neurologic patients tested, including patients with AD, PD, and MS. Low but detectable levels (100–194 pg/mL) were found in a subset of patients with acute lymphocytic leukemia, intracranial tumors, craniocerebral trauma, CNS infections, and GBS. Conclusions: Undetectable CSF hypocretin-1 levels are highly specific to narcolepsy and rare cases of GBS. Measuring hypocretin-1 levels in the CSF of patients suspected of narcolepsy is a useful diagnostic procedure. Low hypocretin levels are also observed in a large range of neurologic conditions, most strikingly in subjects with head trauma. These alterations may reflect focal lesions in the hypothalamus, destruction of the blood brain barrier, or transient or chronic hypofunction of the hypothalamus. Future research in this area is needed to establish functional significance.

1 December 1984 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
DDDonato DiMonte
Donato DiMonte
DRDavid Ross
David Ross
GBGiorgio Bellomo
Giorgio Bellomo
LELena Eklöw
Lena Eklöw
SOSten Orrenius
Sten Orrenius